This study provides real-world insights into the clinical outcomes and management of metastatic melanoma patients treated with ICIs and BRAF/MEKi in both the adjuvant and unresectable setting in a tertiary referral center in Switzerland. The gene discussed is BRAF; the disease is metastatic melanoma.